AstraZeneca PLC (NASDAQ:AZN) Shares Sold by First Affirmative Financial Network

First Affirmative Financial Network decreased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 6.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,638 shares of the company’s stock after selling 302 shares during the period. First Affirmative Financial Network’s holdings in AstraZeneca were worth $314,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Beaird Harris Wealth Management LLC grew its stake in shares of AstraZeneca by 8.9% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 1,851 shares of the company’s stock worth $125,000 after purchasing an additional 151 shares during the last quarter. Bryn Mawr Capital Management LLC grew its stake in shares of AstraZeneca by 0.3% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock worth $4,167,000 after purchasing an additional 164 shares during the last quarter. Drive Wealth Management LLC grew its stake in shares of AstraZeneca by 4.5% in the 4th quarter. Drive Wealth Management LLC now owns 3,911 shares of the company’s stock worth $263,000 after purchasing an additional 170 shares during the last quarter. GM Advisory Group LLC grew its stake in shares of AstraZeneca by 3.5% in the 4th quarter. GM Advisory Group LLC now owns 5,015 shares of the company’s stock worth $338,000 after purchasing an additional 170 shares during the last quarter. Finally, Nordwand Advisors LLC grew its stake in shares of AstraZeneca by 44.5% in the 4th quarter. Nordwand Advisors LLC now owns 578 shares of the company’s stock worth $39,000 after purchasing an additional 178 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AZN stock opened at $78.88 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.70 and a current ratio of 0.89. The stock has a market cap of $244.57 billion, a P/E ratio of 38.67, a P/E/G ratio of 1.41 and a beta of 0.48. The firm has a 50 day simple moving average of $76.48 and a 200 day simple moving average of $69.82. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $80.86.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. The firm had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. Research analysts anticipate that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Argus raised their target price on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. The Goldman Sachs Group initiated coverage on shares of AstraZeneca in a report on Thursday, May 30th. They issued a “buy” rating and a $97.00 target price for the company. Finally, BMO Capital Markets raised their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average price target of $88.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.